Cargando…

Monoclonal antibodies and small-molecules as distinct subclasses of CCR5-targeted therapies for HIV-1

Detalles Bibliográficos
Autor principal:	Olson, William C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716919/ http://dx.doi.org/10.1186/1742-4690-3-S1-S12

Ejemplares similares

Identification of human monoclonal antibodies specific for CCR5 from an antibody library derived from HIV-infected long-term non-progressors
por: Zhang, Mei-Yun, et al.
Publicado: (2006)

Human and chicken antibodies to CCR5-ECL1 block mucosal and systemic HIV infection
por: Lopalco, Lucia, et al.
Publicado: (2006)

Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma
por: Utsunomiya, Atae
Publicado: (2014)

Clearing the HIV reservoir by transplanting CCR5 deficient stem cells
por: Hütter, Gero
Publicado: (2011)

Humanized anti CCR4 antibody KW0761 targets HTLV-1 infected CD4+ CCR4+ and CD8+CCR4+ T cells to treat HAM/TSP
por: Yamano, Yoshihisa, et al.
Publicado: (2015)

Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
por: Brumme, CJ, et al.
Publicado: (2010)

The global distribution of CCR5 delta 32 polymorphism: role in HIV-1 protection
por: Gupta, Anuroopa, et al.
Publicado: (2012)

Search for small molecule activators of latent HIV
por: Geleziunas, Romas, et al.
Publicado: (2012)

Effect of 24 weeks of intensification with a CCR5-antagonist on the decay of the HIV-1 latent reservoir
por: Díaz, L, et al.
Publicado: (2010)

Monoclonal antibodies for the therapy of cancer
por: Simpson, Andrew, et al.
Publicado: (2014)

HIV-1 RNA processing as therapeutic target: characterization of small molecule modulators of HIV-1 RNA processing and transport
por: Wong, Raymond, et al.
Publicado: (2013)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Development of a CCR5-tropic HIV-1 fusion inhibition assay amenable to high-throughput screening for topical microbicides
por: Beer, B, et al.
Publicado: (2006)

Towards targeting protein-protein interfaces with small molecules
por: Gohlke, Holger, et al.
Publicado: (2011)

CCR6 mediates the intracellular HIV inhibitory activity of human beta-defensin 2
por: Sun, Lingling, et al.
Publicado: (2006)

Anti-CCR4 antibody activates virus specific immune response in STLV-1 infected Japanese monkey
por: Sugata, Kenji, et al.
Publicado: (2015)

Co-receptor usage prediction at quasispecies level using ultra-deep pyrosequencing on both circulating and proviral hiv in patients candidates to CCR5 antagonist treatment
por: Abbate, Isabella, et al.
Publicado: (2010)

Chemokine receptor CCR5 mediates resistance to West Nile Virus infection in mouse and man
por: Murphy, Philip
Publicado: (2006)

Chemokines in rheumatoid arthritis: novel, potential therapeutic targets of the CCR2 chemokine receptor signaling pathway
por: Matsushima, K, et al.
Publicado: (2003)

Use of phage display technology for the selection of monoclonal antibodies in allergen research and diagnostics
por: Vandekerckhove, Marjolein, et al.
Publicado: (2014)

Multi-omics approach for comparative studies of monoclonal antibody producing CHO cells
por: Orellana, Camila A, et al.
Publicado: (2015)

The molecules and mechanisms of heart development, disease and regeneration
por: Olson, Eric N
Publicado: (2014)

Anti-CD3 monoclonal antibody as a possible therapeutic alternative in HAM/TSP
por: Van Weyenbergh, Johan, et al.
Publicado: (2014)

Impact of IgG subclass on monoclonal antibody developability
por: Cain, Paul, et al.
Publicado: (2023)

S04-04 OA. HIV-specific responses induced by anti-CD40 targeting antibodies
por: Loof, N, et al.
Publicado: (2009)

A quantitative and mechanistic model for monoclonal antibody glycosylation as a function of nutrient availability during cell culture
por: Jiménez del Val, Ioscani, et al.
Publicado: (2013)

Natural and engineered antibodies against HIV
por: Berger, Edward A
Publicado: (2006)

Impact of IgG subclass on molecular properties of monoclonal antibodies
por: Tang, Yu, et al.
Publicado: (2021)

Towards gene therapy against HIV-1: new therapeutic target in gag RNA accessible to ribozymes and RNA interference molecules
por: Gatignol, A, et al.
Publicado: (2014)

Anti-Fas IgM monoclonal antibody (anti-Fas mAb) effect on haemophilic arthropathy (HA) synoviocytes
por: Guiducci, Serena, et al.
Publicado: (2012)

Understanding the impact of different bioprocess conditions on monoclonal antibody glycosylation in CHO cell cultures through experimental and computational analyses
por: Sou, Si N, et al.
Publicado: (2015)

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
por: Harvey, Christopher, et al.
Publicado: (2015)

Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
por: Berro, Reem, et al.
Publicado: (2009)

A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
por: Eisenberg, R, et al.
Publicado: (2003)

Complete prevention of HTLV-1 infection in humanized mice (hu-PBL SCID) by a neutralizing monoclonal antibody to envelope gp46
por: Saito, Mineki, et al.
Publicado: (2014)

Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis
por: Bracaglia, C, et al.
Publicado: (2015)

Quantifying the shifts in physicochemical property space introduced by the metabolism of small organic molecules
por: Kirchmair, Johannes, et al.
Publicado: (2013)

SHIVs, monkeys, and anti-HIV-1 neutralizing antibodies
por: Martin, Malcolm A
Publicado: (2013)

Complement supports progression of HIV and turns neutralising antibodies at low concentration into infection enhancing antibodies
por: Dierich, Manfred P, et al.
Publicado: (2006)

S021-06 OA. Potent and broad neutralizing antibodies from HIV-1 non-clade B infected donor reveal a new HIV-1 vaccine target
por: Phogat, SK, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_f8ad1iu363p7gevpe8v4c9dn1d